 The aim of this study is to assess the effect of LCIG levodopa-carbidopa intestinal gel on HRQL Health-Related Quality of Life of participants and compare the Health-Related Quality of Life between participants continuing to levodopa-carbidopa intestinal gel treatments versus participants continuing on oral therapy for Parkinsons Disease. 